[{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avenzo Therapeutics \/ New Enterprise Associates","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ New Enterprise Associates"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Allorion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"AVZO-023","moa":"CDK4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AVZO-1418","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Avenzo Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : AVZO-1418, a potential best-in-class, novel EGFR/HER3 bispecific antibody-drug conjugate. It is being evaluated for the treatment of advanced solid tumors.

                          Product Name : AVZO-1418

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          May 22, 2025

                          Lead Product(s) : AVZO-1418

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Under the licensing agreement, Avenzo has exercised its exclusive option for global (excluding Greater China) development, manufacturing, and commercialization rights for AVZO-023.

                          Product Name : AVZO-023

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 21, 2025

                          Lead Product(s) : AVZO-023

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : Allorion Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Proceeds will advance Avenzo’s ARTS-021, a selective CDK2 inhibitor in a Phase 1 study for HR+/HER2- metastatic breast cancer and other advanced solid tumors.

                          Product Name : AVZO-021

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 26, 2024

                          Lead Product(s) : AVZO-021,Fulvestrant,Letrozole

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : New Enterprise Associates

                          Deal Size : $150.0 million

                          Deal Type : Series A Financing

                          blank

                          04

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The collaboration aims to evaluate AVZO-021, a best-in-class CDK2 inhibitor, in combination with Gilead’s Trodelvy (sacituzumab govitecan), for patients with HR-positive, HER2-negative breast cancer.

                          Product Name : AVZO-021

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 09, 2024

                          Lead Product(s) : AVZO-021,Sacituzumab Govitecan

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Gilead Sciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank